Notable Labs (United States)

Recent papers from Notable Labs (United States)

1. Abstract 2594: A deep sampling and single molecule digital counting assay for rare molecule detectionCancer Research · 2026
2. From Surviving to Thriving: A Qualitative Study of Adapting Telehealth Systems for Specialty Diabetes Care Across Four California Medical CentersClinical Diabetes · 2024
3. Abstract 5178: Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patientsCancer Research · 2024
4. Abstract 2548: Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samplesCancer Research · 2024
5. Ex vivo discovery of synergistic drug combinations for hematologic malignanciesSLAS DISCOVERY · 2023
6. Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AMLCancers · 2022
7. Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid LeukemiaFrontiers in Oncology · 2022
8. The risks of election believability (or lack thereof)Communications of the ACM · 2021
9. Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expressionTranslational Oncology · 2020
10. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaBlood · 2020
11. Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasmsBlood Advances · 2020
12. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyClinical Cancer Research · 2019
13. Scoping identity theftCommunications of the ACM · 2006
14. Analyzing security costsCommunications of the ACM · 2003